RESUMO
We report the case of a 60-year old female patient with advanced severe lung injury as a consequence of COVID-19-pneumonia. The patient was initially treated with highflow oxygen via nasal cannula (HFNC) and CPAP for two days but had to be intubated and mechanically ventilated. After failure of mechanical ventilation because of persistant severe hypoxemia treatment was switched to ECMO which was applicated for 24 days. Prognostic parameters indicated a favourable trend after day 14. After discontinuation of ECMO and 11 days of intermittent assisted ventilation via tracheostoma and low dose oxygen (1âl/min), the patient could be transferred to rehabilitation. The last chest radiograph prior to transferral revealed a nearly complete resolution of bilateral pulmonary infiltrates. Our case demonstrates that severe COVID-19-associated lung injury can be reversible even after prolonged ECMO.
Assuntos
Infecções por Coronavirus/complicações , Coronavirus , Oxigenação por Membrana Extracorpórea/métodos , Pneumonia Viral/complicações , Síndrome do Desconforto Respiratório/terapia , Insuficiência Respiratória/terapia , Betacoronavirus , COVID-19 , Infecções por Coronavirus/virologia , Feminino , Humanos , Pulmão/fisiopatologia , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/virologia , Síndrome do Desconforto Respiratório/etiologia , SARS-CoV-2 , Resultado do TratamentoRESUMO
OBJECTIVE: Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. METHOD: Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorders. Response was defined as an initial 20% PANSS total score reduction at discharge, remission was defined according to the proposed consensus criteria by the Remission in Schizophrenia Working Group. RESULTS: Suicidal patients (22%) scored significantly higher on the PANSS negative subscore, PANSS insight item and HAMD total score at admission and at discharge. They developed significantly more side effects. No differences were found concerning response and remission between the two patient subgroups. CONCLUSION: Despite receiving significantly more antidepressants the suicidal patients suffered from significantly more depressive symptoms up to discharge, yet without differing regarding response and remission.
Assuntos
Esquizofrenia/epidemiologia , Psicologia do Esquizofrênico , Tentativa de Suicídio/psicologia , Tentativa de Suicídio/estatística & dados numéricos , Doença Aguda , Adulto , Acatisia Induzida por Medicamentos/diagnóstico , Acatisia Induzida por Medicamentos/epidemiologia , Acatisia Induzida por Medicamentos/psicologia , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Estudos de Coortes , Comorbidade , Estudos Transversais , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/epidemiologia , Transtorno Depressivo Maior/psicologia , Feminino , Alemanha , Inquéritos Epidemiológicos , Hospitais Universitários , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Fatores de Risco , Esquizofrenia/diagnóstico , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) compared with transition from other oral second generation antipsychotics. METHODS: Stable in- or outpatients (n=206) receiving RIS or OQAZ (olanzapine, quetiapine, amisulpride, ziprasidone) were transitioned to RLAI for 12 weeks. The primary outcome was the between-group treatment difference in change in PANSS total score from baseline to endpoint. Secondary outcomes included health-related quality-of-life and therapeutic alliance. RESULTS: Mean between-group difference in the change in PANSS total score from baseline to endpoint was -6.1 (CI: -17.6, 5.4), suggesting greater improvement in OQAZ than RIS patients. Due to the pre-specified non-inferiority margin of 5.1, it could not be concluded that OQAZ pre-treatment results in an at least non-inferior PANSS reduction versus RIS pre-treatment. Patient satisfaction with medication and change in quality-of-life subscores showed advantages for OQAZ patients. DISCUSSION: Compared to RIS pre-treatment, clinically stable patients with schizophrenia who are pre-treated with OQAZ might draw a stronger clinical benefit from direct transition to RLAI.
Assuntos
Antipsicóticos/administração & dosagem , Antipsicóticos/uso terapêutico , Risperidona/administração & dosagem , Risperidona/uso terapêutico , Esquizofrenia/tratamento farmacológico , Administração Oral , Adulto , Preparações de Ação Retardada , Feminino , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Prospectivos , Escalas de Graduação Psiquiátrica , Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
AIMS: Although shared decision-making (SDM) has the potential to improve health outcomes, psychiatrists often exclude patients with more severe mental illnesses or more acute conditions from participation in treatment decisions. This study examines whether SDM is facilitated by an approach which is specifically adapted to the needs of acutely ill patients (SDM-PLUS). METHODS: The study is a multi-centre, cluster-randomised, non-blinded, controlled trial of SDM-PLUS in 12 acute psychiatric wards of five psychiatric hospitals addressing inpatients with schizophrenia or schizoaffective disorder. All patients fulfilling the inclusion criteria were consecutively recruited for the trial at the time of their admission to the ward. Treatment teams of intervention wards were trained in the SDM-PLUS approach through participation in two half-day workshops. Patients on intervention wards received group training in SDM. Staff (and patients) of the control wards acted under 'treatment as usual' conditions. The primary outcome parameter was the patients' perceived involvement in decision-making at 3 weeks after study enrolment, analysed using a random-effects linear regression model. RESULTS: In total, 161 participants each were recruited in the intervention and control group. SDM-PLUS led to higher perceived involvement in decision-making (primary outcome, analysed patients n = 257, mean group difference 16.5, 95% CI 9.0-24.0, p = 0.002, adjusted for baseline differences: ß 17.3, 95% CI 10.8-23.6, p = 0.0004). In addition, intervention group patients exhibited better therapeutic alliance, treatment satisfaction and self-rated medication compliance during inpatient stay. There were, however, no significant improvements in adherence and rehospitalisation rates in the 6- and 12-month follow-up. CONCLUSIONS: Despite limitations in patient recruitment, the SDM-PLUS trial has shown that the adoption of behavioural approaches (e.g. motivational interviewing) for SDM may yield a successful application to mental health. The authors recommend strategies to ensure effects are not lost at the interface between in- and outpatient treatment.Trial registration: The trial was registered at Deutsches Register Klinischer Studien (DRKS00010880).
Assuntos
Tomada de Decisões , Pacientes Internados/psicologia , Participação do Paciente , Esquizofrenia/terapia , Adulto , Comunicação , Feminino , Humanos , Masculino , Adesão à Medicação , Pessoa de Meia-Idade , Avaliação de Processos e Resultados em Cuidados de Saúde , Unidade Hospitalar de Psiquiatria , Psicologia do Esquizofrênico , Adulto JovemRESUMO
Schizophrenia is one of the most expensive illnesses. Antipsychotics are an essential component of the acute and preventative treatment of this illness, and long-term treatment is necessary to decrease the risk of psychotic relapse. The efficacy and tolerability of flupentixol was evaluated in a post-marketing surveillance study (PMS) in schizophrenic patients receiving long-term treatment in routine clinical practice. Psychiatrists in office practice treated patients for approximately 10 weeks, with a subsequent follow-up period of up to 18 months. We here report on the follow-up period in 128 patients. The benefit for schizophrenic patients increased with the treatment duration of flupentixol as documented by the Clinical Global Impression (CGI). Subjective quality of life improved during the first study period, and this remained stable in the follow-up period. No increase in body weight was observed during the study. The relapse rate was much lower than in other studies. Anticholinergic medication was necessary for 22.7% of the patients at any time. More than 70% of the psychiatrists involved evaluated the treatment as very good or good. The results of this study suggest that flupentixol is a potent and safe antipsychotic for the long-term treatment of schizophrenia in routine clinical practice.
Assuntos
Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Flupentixol/administração & dosagem , Flupentixol/efeitos adversos , Vigilância de Produtos Comercializados , Qualidade de Vida/psicologia , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Adulto , Feminino , Seguimentos , Humanos , Masculino , Fatores de Tempo , Resultado do TratamentoRESUMO
Various pharmacological strategies have been developed to treat such refractory depression, of which combination therapies with antidepressants are one of the most important. This article reviews both benefits and risks of all known antidepressant combination strategies. The relevant literature was identified by means of a computerized MEDLINE research on the years 1990-2006 and scanning of review articles. The use of antidepressant combinations to overcome refractory depression is a common strategy in practice. Many antidepressants can be usefully combined especially if they engage separate mechanisms of action--like SSRIs with Reboxetine, Bupropion, Mirtazapine and Tricyclics--or on the other hand--Tricyclics with MAO-Inhibitiors. Combination strategies are effective treatment options, however they do have potential safety risks due to pharmacokinetic and pharmacodynamic interactions. Combinations including MAOIs can cause serotonin syndrome, and some SSRIs like Fluoxetine may elevate tricyclic plasma levels with the consequence of an increased risk of toxicity. The distinct knowledge of available antidepressant combination strategies may help to increase response--as well as remission rates in therapy resistant depression. However, further research is urgently needed to determine relative efficacy.
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/psicologia , Antidepressivos Tricíclicos/uso terapêutico , Resistência a Medicamentos , Quimioterapia Combinada , Humanos , Inibidores da Monoaminoxidase/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêuticoAssuntos
Transtornos Mentais/tratamento farmacológico , Segurança do Paciente , Psicofarmacologia/história , Comunicação , Psiquiatria Legal , História do Século XX , História do Século XXI , Humanos , Transtornos Mentais/diagnóstico , Cooperação do Paciente , Segurança do Paciente/economia , Segurança do Paciente/história , Farmacoepidemiologia , Farmacovigilância , Psiquiatria/história , Projetos de Pesquisa , Medição de RiscoAssuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Segurança do Paciente , Psicofarmacologia , Psicotrópicos/efeitos adversos , Interações Medicamentosas , Monitoramento de Medicamentos , Quimioterapia Combinada , Humanos , Assistência de Longa Duração , Transtornos Mentais/tratamento farmacológico , Cooperação do Paciente , Farmacocinética , Psicotrópicos/uso terapêuticoAssuntos
Transtorno Depressivo/terapia , Terapia por Estimulação Elétrica , Antidepressivos/administração & dosagem , Antidepressivos/uso terapêutico , Antipsicóticos/uso terapêutico , Terapia Combinada , Transtorno Depressivo/tratamento farmacológico , Resistência a Medicamentos , Estrogênios/uso terapêutico , Humanos , Compostos de Lítio/uso terapêutico , Fototerapia , Estimulação Magnética Transcraniana , Tri-Iodotironina/uso terapêuticoAssuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/terapia , Psicoterapia , Terapia Cognitivo-Comportamental , Transtorno Depressivo Maior/complicações , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/metabolismo , Resistência a Medicamentos , Humanos , Valor Preditivo dos Testes , Terminologia como AssuntoRESUMO
BACKGROUND: Aim was to examine depressive symptoms in acutely ill schizophrenia patients on a single symptom basis and to evaluate their relationship with positive, negative and general psychopathological symptoms. METHODS: Two hundred and seventy-eight patients suffering from a schizophrenia spectrum disorder were analysed within a naturalistic study by the German Research Network on Schizophrenia. Using the Calgary Depression Scale for Schizophrenia (CDSS) depressive symptoms were examined and the Positive and Negative Syndrome Scale (PANSS) was applied to assess positive, negative and general symptoms. Correlation and factor analyses were calculated to detect the underlying structure and relationship of the patient's symptoms. RESULTS: The most prevalent depressive symptoms identified were depressed mood (80%), observed depression (62%) and hopelessness (54%). Thirty-nine percent of the patients suffered from depressive symptoms when applying the recommended cut-off of a CDSS total score of >6 points at admission. Negligible correlations were found between depressive and positive symptoms as well as most PANSS negative and global symptoms despite items on depression, guilt and social withdrawal. The factor analysis revealed that the factor loading with the PANSS negative items accounted for most of the data variance followed by a factor with positive symptoms and three depression-associated factors. LIMITATIONS: The naturalistic study design does not allow a sufficient control of study results for the effect of different pharmacological treatments possibly influencing the appearance of depressive symptoms. CONCLUSION: Results suggest that depressive symptoms measured with the CDSS are a discrete symptom domain with only partial overlap with positive or negative symptoms.
Assuntos
Depressão/diagnóstico , Culpa , Esquizofrenia/diagnóstico , Psicologia do Esquizofrênico , Doença Aguda , Adulto , Afeto , Análise Fatorial , Feminino , Alemanha , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Escalas de Graduação Psiquiátrica , Projetos de Pesquisa , Índice de Gravidade de DoençaRESUMO
A comparison of the effect on growth hormone (GH) stimulation in men (n = 6) of desimipramine (DMI), a tricyclic antidepressant, and of the benzodiazepine derivatives diazepam and metaclazepam with that of a placebo, showed that only DMI caused a significant (p less than 0.01) GH stimulation. After DMI, all six subjects showed a GH stimulation greater than 7.5 ng/ml, whereas after diazepam or metaclazepam, only three of the six subjects showed GH stimulation greater than 7.5 ng/ml, and the other three showed only a very small change, or no change at all in GH secretion. Higher GH stimulation occurred after diazepam (10 mg i.v.) than after diazepam (10 mg p.o.). No dose-dependent difference in GH stimulation after metaclazepam (10 and 30 mg p.o.) was apparent. No side effects appeared after administration of DMI during the test period (180 min); however, after administration of the benzodiazepine derivatives, sedative effects were clearly noted. DMI thus causes reliable GH stimulation in healthy male subjects, whereas GH stimulation could only be measured in some of the subjects after diazepam and metaclazepam.
Assuntos
Ansiolíticos , Benzodiazepinas/farmacologia , Desipramina/farmacologia , Diazepam/farmacologia , Hormônio do Crescimento/sangue , Adulto , Relação Dose-Resposta a Droga , Humanos , Masculino , Fatores de TempoRESUMO
Phentolamine, a postsynaptic noradrenergic (NA) receptor blocker, inhibits diazepam-induced growth hormone (GH) secretion in man. In order to study the effect of phentolamine on six healthy subjects with a diazepam (10 mg i.v.)-induced GH increase greater than 7.5 ng/ml, it was necessary to test 11 subjects. The six diazepam GH responders showed a significantly higher (p less than 0.01) GH stimulation after diazepam alone than after diazepam plus phentolamine (60 mg i.v.). The inhibitory effect of phentolamine suggests that NA alpha receptors are involved in the diazepam-induced GH increase. Prolactin secretion after administration of diazepam (10 mg i.v.) was only slightly elevated in comparison with placebo (i.v.), suggesting that diazepam does not have an agonistic effect on dopamine (DA) receptors.
Assuntos
Diazepam/farmacologia , Hormônio do Crescimento/sangue , Fentolamina/farmacologia , Prolactina/sangue , Humanos , MasculinoRESUMO
Tolerability of long term clozapine treatment (7-8 years) was investigated in 27 female patients (age 34-77 years). Diagnosis according to ICD 9 was schizophrenia in 21 patients, severe psychomotor agitation with mental deficiency in 4 patients and an "endogenous" depression in 2 patients. All patients had previously been treated with different neuroleptics but with inadequate response or distressing side effects. The duration of the disorder was 10-36 years, duration of hospitalisation 10-36 years. At the day of investigation the total dose of clozapine ranged from 52-826 g, the average total dose being 385 g. The daily dose of clozapine ranged from 75 to 600 mg, the average daily dose being 225 mg. Only 2 patients were treated exclusively with clozapine, the other 25 patients were also receiving other neuroleptics. Seventy eight per cent of the investigated patients complained about hypersalivation and 63% showed overweight. In 37% of the patients the EEG demonstrated abnormalities. Mild parkinsonism was reported in 15% and akathisia in 11% of the patients, all these patients being on combined treatment. Clozapine did not induce tardive dysakinesia (TD) in any of the patients within a treatment period of 7-8 years. It is concluded that a potential benefit of clozapine includes a low incidence of neurological side effects even after long term administration.
Assuntos
Clozapina/efeitos adversos , Dibenzazepinas/efeitos adversos , Adulto , Idoso , Doenças dos Gânglios da Base/induzido quimicamente , Clozapina/uso terapêutico , Tolerância a Medicamentos , Eletroencefalografia , Feminino , Humanos , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológico , Psicologia do EsquizofrênicoRESUMO
1. One aspect of using MAO-inhibitors - combining them with tricyclic antidepressants in the treatment of therapy resistant depression - has always been controversely discussed in regard to its unusual toxicity and efficacy. 2. To obtain detailled information about safety and efficacy of such a combined treatment, the charts of 94 inpatients treated with a tranylcypromine - tri- (tetra) cyclic antidepressant combination were reviewed. 3. Within a mean treatment period of 21.9 days, 68% of the patients demonstrated a very good or good improvement to combined treatment, the most effective combination being tranylcypromine + amitriptyline. 4. The incidence of side effects among the patients on the combined regimen was slightly, but not significantly lower as compared to the patients on single tri- (tetra) cyclic antidepressant treatment. 5. Our retrospective study supports the general safety and efficacy of combined MAOI-TCA treatment and suggests that combined treatment, if properly administered, leads to neither serious complications nor an inordinate number of side effects.
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Tranilcipromina/uso terapêutico , Trifluoperazina/uso terapêutico , Antidepressivos/efeitos adversos , Pressão Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Transtorno Depressivo/psicologia , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Frequência Cardíaca/efeitos dos fármacos , Humanos , Tranilcipromina/efeitos adversos , Trifluoperazina/efeitos adversosAssuntos
Anticonvulsivantes/uso terapêutico , Antimaníacos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Carbonato de Lítio/uso terapêutico , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/farmacocinética , Antimaníacos/efeitos adversos , Antimaníacos/farmacocinética , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Transtorno Bipolar/sangue , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/psicologia , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Quimioterapia Combinada , Humanos , Carbonato de Lítio/efeitos adversos , Carbonato de Lítio/farmacocinéticaRESUMO
BACKGROUND: Studies in urban areas identified environmental risk factors for mental illness, but little research on this topic has been performed in rural areas. METHODS: Hospital admission rates were computed for 174 rural municipalities in the catchment area of the state psychiatric hospital in Günzburg in years 2006 to 2009 and combined with structural and socio-economic data. Relationships of overall and diagnosis-specific admission rates with municipality characteristics were analysed by means of negative binomial regression models. RESULTS: Admission rates of patients with a diagnosis of schizophrenia and affective disorder combined decrease with increasing population growth, population density, average income and green areas, while admission rates are positively correlated with commuter balance, income inequality, unemployment rates and traffic areas. Admission rates for schizophrenia are negatively related to population growth, average income and agricultural areas, but positively related to mobility index, income inequality and unemployment rate. Admission rates for affective disorders are negatively related to population growth, population density, average income and green areas, while higher admission rates are correlated with commuter balance, high income inequality, unemployment rate and traffic-related areas. CONCLUSIONS: Effects of wealth, economic inequality, population density and structural area characteristics influence psychiatric admission rates also in rural areas.